Situación actual y perspectivas en el tratamiento de las leishmaniasis tegumentarias en América
Palabras clave:
leishmaniasis
Descargas
La descarga de datos todavía no está disponible.
Referencias
Chakravarty J, Sundar S. Current and emerging medications for the treatment of leishmaniasis. Expert Opin Pharmacother. 2019;7:1-15. https://doi.org/10.1080/14656566.2019.1609940
Hefnawy A, Berg M, Dujardin JC, De Muylder G. Exploiting knowledge on leishmania drug resistance to support the quest for new drugs. Trends Parasitol. 2017;33:162-174. https://doi.org/10.1016/j.pt.2016.11.003
Sampaio RNR, Silva JSFE, Paula CDR, Porto C, Motta JOCD, Pereira LIA, et al. A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis. Rev Soc Bras Med Trop. 2019;28;52:e20180292. https://doi.org/10.1590/0037-8682-0292-2018
Machado GU, Prates FV, Machado PRL. Disseminated leishmaniasis: Clinical, pathogenic, and therapeutic aspects. An Bras Dermatol. 2019;94:9-16.
https://doi.org/10.1590/abd1806-4841.20198775
Sosa N, Pascale JM, Jiménez AI, Norwood JA, Kreishman-Detrick M, Weina PJ, et al. Topical paromomycin for New World cutaneous leishmaniasis. PLoS Negl Trop Dis. 2019;2;13(5):e0007253. https://doi.org/ 10.1371/journal.pntd.0007253
Iranpour S, Hosseinzadeh A, Alipour A. Efficacy of miltefosine compared with glucantime for the treatment of cutaneous leishmaniasis: A systematic review and meta-analysis. Epidemiol Health. 2019;31:e2019011. https://doi.org/10.4178/epih.e2019011
Hefnawy A, Berg M, Dujardin JC, De Muylder G. Exploiting knowledge on leishmania drug resistance to support the quest for new drugs. Trends Parasitol. 2017;33:162-174. https://doi.org/10.1016/j.pt.2016.11.003
Sampaio RNR, Silva JSFE, Paula CDR, Porto C, Motta JOCD, Pereira LIA, et al. A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis. Rev Soc Bras Med Trop. 2019;28;52:e20180292. https://doi.org/10.1590/0037-8682-0292-2018
Machado GU, Prates FV, Machado PRL. Disseminated leishmaniasis: Clinical, pathogenic, and therapeutic aspects. An Bras Dermatol. 2019;94:9-16.
https://doi.org/10.1590/abd1806-4841.20198775
Sosa N, Pascale JM, Jiménez AI, Norwood JA, Kreishman-Detrick M, Weina PJ, et al. Topical paromomycin for New World cutaneous leishmaniasis. PLoS Negl Trop Dis. 2019;2;13(5):e0007253. https://doi.org/ 10.1371/journal.pntd.0007253
Iranpour S, Hosseinzadeh A, Alipour A. Efficacy of miltefosine compared with glucantime for the treatment of cutaneous leishmaniasis: A systematic review and meta-analysis. Epidemiol Health. 2019;31:e2019011. https://doi.org/10.4178/epih.e2019011
Cómo citar
Soto, J. (2019). Situación actual y perspectivas en el tratamiento de las leishmaniasis tegumentarias en América. Biomédica, 39(2), 237-240. https://doi.org/10.7705/biomedica.5111
Publicado
2019-06-15
Número
Sección
Editorial
Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir los artículos ni sus resúmenes, sin previa autorización escrita del Comité Editorial de la revista Biomédica
